Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Bias, spin, and misreporting: time for full access to trial protocols and results.

Chan AW.

PLoS Med. 2008 Nov 25;5(11):e230. doi: 10.1371/journal.pmed.0050230. No abstract available.

PMID:
19067481
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Publication bias and the efficacy of antidepressants.

Mathew SJ, Charney DS.

Am J Psychiatry. 2009 Feb;166(2):140-5. doi: 10.1176/appi.ajp.2008.08071102. No abstract available.

PMID:
19188290
[PubMed - indexed for MEDLINE]
3.

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.

Rising K, Bacchetti P, Bero L.

PLoS Med. 2008 Nov 25;5(11):e217; discussion e217. doi: 10.1371/journal.pmed.0050217. Erratum in: PLoS Med. 2009 Jan;6(1). doi: 10.1371/journal.Pmed.1000017.

PMID:
19067477
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Association of trial registration with the results and conclusions of published trials of new oncology drugs.

Rasmussen N, Lee K, Bero L.

Trials. 2009 Dec 16;10:116. doi: 10.1186/1745-6215-10-116.

PMID:
20015404
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2012 Jun;73(6):856-64. doi: 10.4088/JCP.11r07539. Epub 2012 May 15. Review.

PMID:
22687813
[PubMed - indexed for MEDLINE]
6.

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.

Alper K, Schwartz KA, Kolts RL, Khan A.

Biol Psychiatry. 2007 Aug 15;62(4):345-54. Epub 2007 Jan 16.

PMID:
17223086
[PubMed - indexed for MEDLINE]
7.

Publication of clinical trials supporting successful new drug applications: a literature analysis.

Lee K, Bacchetti P, Sim I.

PLoS Med. 2008 Sep 23;5(9):e191. doi: 10.1371/journal.pmed.0050191.

PMID:
18816163
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
[PubMed - indexed for MEDLINE]
9.

Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.

Peck CC, Rubin DB, Sheiner LB.

Clin Pharmacol Ther. 2003 Jun;73(6):481-90. Review. No abstract available.

PMID:
12811358
[PubMed - indexed for MEDLINE]
10.

Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development.

Fries JF, Krishnan E.

Arthritis Res Ther. 2004;6(3):R250-5. Epub 2004 Mar 18.

PMID:
15142271
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Insomnia medication: do published studies reflect the complete picture of efficacy and safety?

Mattila T, Stoyanova V, Elferink A, Gispen-de Wied C, de Boer A, Wohlfarth T.

Eur Neuropsychopharmacol. 2011 Jul;21(7):500-7. doi: 10.1016/j.euroneuro.2010.10.005. Epub 2010 Nov 16.

PMID:
21084176
[PubMed - indexed for MEDLINE]
12.

Improving access to FDA reviews and documents.

Mathis LL, Pica-Branco D, Tassinari MS.

JAMA. 2009 Nov 25;302(20):2204-5; author reply 2205. doi: 10.1001/jama.2009.1727. No abstract available.

PMID:
19934419
[PubMed - indexed for MEDLINE]
13.

Carvedilol and the Food and Drug Administration approval process: an introduction.

Fisher LD, Moyé LA.

Control Clin Trials. 1999 Feb;20(1):1-15.

PMID:
10027497
[PubMed - indexed for MEDLINE]
14.

Failure rate and "professional subjects" in clinical trials of major depressive disorder.

Shiovitz TM, Zarrow ME, Shiovitz AM, Bystritsky AM.

J Clin Psychiatry. 2011 Sep;72(9):1284; author reply 1284-5. doi: 10.4088/JCP.11lr07229. No abstract available.

PMID:
21951988
[PubMed - indexed for MEDLINE]
15.

Adjusting for publication biases across similar interventions performed well when compared with gold standard data.

Moreno SG, Sutton AJ, Ades AE, Cooper NJ, Abrams KR.

J Clin Epidemiol. 2011 Nov;64(11):1230-41. doi: 10.1016/j.jclinepi.2011.01.009. Epub 2011 May 6.

PMID:
21530169
[PubMed - indexed for MEDLINE]
16.

The need for improved access to FDA reviews.

O'Connor AB.

JAMA. 2009 Jul 8;302(2):191-3. doi: 10.1001/jama.2009.973. No abstract available.

PMID:
19584349
[PubMed - indexed for MEDLINE]
17.

Distorting, misrepresenting and slanting research results.

Glick M.

J Am Dent Assoc. 2010 Sep;141(9):1049-50. No abstract available. Erratum in: J Am Dent Assoc. 2011 Feb;142(2):133.

PMID:
20807897
[PubMed - indexed for MEDLINE]
18.

Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet.

Al-Marzouki S, Roberts I, Evans S, Marshall T.

Lancet. 2008 Jul 19;372(9634):201. doi: 10.1016/S0140-6736(08)61060-0. No abstract available.

PMID:
18640445
[PubMed - indexed for MEDLINE]
19.

Overhauling clinical trials.

Scott CT, Baker M.

Nat Biotechnol. 2007 Mar;25(3):287-92. No abstract available.

PMID:
17344876
[PubMed - indexed for MEDLINE]
20.

FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.

Mitka M.

JAMA. 2012 Jun 27;307(24):2576-7. doi: 10.1001/jama.2012.6684. No abstract available.

PMID:
22735406
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk